Evidence map›Paper›PMID 37511621›Full record

ReviewInternational journal of molecular sciences2023

Recent Progress in the Characterization, Synthesis, Delivery Procedures, Treatment Strategies, and Precision of Antimicrobial Peptides.

Olalekan Olanrewaju Bakare, Arun Gokul, Lee-Ann Niekerk, Omolola Aina, Ademola Abiona, Adele Mariska Barker, Gerhard Basson, Mbukeni Nkomo, Laetitia Otomo, Marshall Keyster and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Olalekan Olanrewaju BakareDepartment of Biochemistry, Faculty of Basic Medical Sciences, Olabisi Onabanjo University, Sagamu 2002, Nigeria.ORCID 0000-0002-5856-8286
Arun GokulDepartment of Plant Sciences, Qwaqwa Campus, University of the Free State, Phuthadithjaba 9866, South Africa.ORCID 0000-0003-1575-0632
Lee-Ann NiekerkEnvironmental Biotechnology Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.ORCID 0000-0002-9788-3131
Omolola AinaPlant Omics Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.
Ademola AbionaDepartment of Biochemistry, Faculty of Basic Medical Sciences, Olabisi Onabanjo University, Sagamu 2002, Nigeria.
Adele Mariska BarkerEnvironmental Biotechnology Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.
Gerhard BassonEnvironmental Biotechnology Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.
Mbukeni NkomoDepartment of Botany, H13 Botany Building, University of Zululand, Private Bag X1001, KwaDlangezwa 3886, South Africa.ORCID 0000-0002-7652-1588
Laetitia OtomoDepartment of Plant Sciences, Qwaqwa Campus, University of the Free State, Phuthadithjaba 9866, South Africa.ORCID 0000-0002-3635-2759
Marshall KeysterEnvironmental Biotechnology Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.ORCID 0000-0002-8718-736X
Ashwil KleinPlant Omics Laboratory, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.ORCID 0000-0002-5606-886X
University of the Western Cape · ZAOlabisi Onabanjo University · NGUniversity of the Free State · ZAUniversity of Zululand · ZA

Funding

Wellcome Trust 109083
6 · The paper itself

Abstract

Infectious diseases are constantly evolving to bypass antibiotics or create resistance against them. There is a piercing alarm for the need to improve the design of new effective antimicrobial agents such as antimicrobial peptides which are less prone to resistance and possess high sensitivity. This would guard public health in combating and overcoming stubborn pathogens and mitigate incurable diseases; however, the emergence of antimicrobial peptides' shortcomings ranging from untimely degradation by enzymes to difficulty in the design against specific targets is a major bottleneck in achieving these objectives. This review is aimed at highlighting the recent progress in antimicrobial peptide development in the area of nanotechnology-based delivery, selectivity indices, synthesis and characterization, their doping and coating, and the shortfall of these approaches. This review will raise awareness of antimicrobial peptides as prospective therapeutic agents in the medical and pharmaceutical industries, such as the sensitive treatment of diseases and their utilization. The knowledge from this development would guide the future design of these novel peptides and allow the development of highly specific, sensitive, and accurate antimicrobial peptides to initiate treatment regimens in patients to enable them to have accommodating lifestyles.

Indexed as

Anti-Infective AgentsCommunicable DiseasesAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesHumansAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptidesantimicrobial peptidesbroad-spectrumcharacterizationcoatingdopingsynthesis

Identifiers

PMID37511621
PMCPMC10380191
OpenAlexW4385241738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.